Showing 76–100 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Strydom N, van Wijk RC, Wang Q, Ernest JP, Chaba L, et al.
…g discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare results between experiments. Using published treatment efficacy data from a mouse tubercu…
Jason E Cummings, Lisa Woolhiser, Barbara Graham, Gregory T Robertson, M Nurul Islam, et al.
…ls is essential for optimizing and prioritizing therapeutic regimens. However, standardized classification methods for comparing high-performing regimens are currently lacking. This study defines a quantitative framework utilizing rifampicin-based regimens in a high-burden aeroso…
Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, et al.
…ic response surface (PRS) platform, we have identified drug regimens that treat tuberculosis more rapidly in mice than the current Standard Regimen used in humans. We show that PRS Regimen III, comprising clofazimine, SQ109, bedaquiline and pyrazinamide, rapidly sterilizes the lu…
Beijing Chest Hospital
The goal of this clinical trial is to compare the efficacy and safety of a Contezolid and Delamanid-Containing short regimen to standard longer regimen in Rifampicin-resistant pulmonary tuberculosis (RR-TB). The main questions it aims to answer are: * Is the efficacy of short re…
Sophia B. Georghiou, Margaretha de Vos, Kavindhran Velen, Paolo Miotto, Rebecca E. Colman, et al.
…ber of novel and repurposed anti-tuberculosis compounds and regimens, there remains a large number of drugs for which no rapid and accurate molecular diagnostic option exists. The lack of rapid drug susceptibility testing for linezolid, bedaquiline, clofazimine, the nitroimidazol…
Natalia Yatskevich, Henadz Hurevich, Varvara Solodovnikova, E Garsevanidze, Nathalie Lachenal, et al.
… 2022 was 18-20 months. The efficacy of treatment with such regimens is low, with the WHO’s Global TB Report suggesting that efficacy was around 73% in Belarus in 2018. The development of effective short regimens for RR-TB treatment is urgent. In Belarus, six-month long treatment…
Kaushik A, Ammerman NC, Tasneen R, Lachau-Durand S, Andries K, et al.
…of long-acting bedaquiline and 2 ) evaluate the activity of regimens comprised of long-acting bedaquiline plus short (2-4 wk) oral companion courses of bedaquiline, with or without rifapentine, using the validated mouse model of tuberculosis preventive therapy. Methods: After the…
М. Ф. Губкина, Yu. Yu. Khokhlovа, I. Yu. Petrаkovа, N. V. Yukhimenko
…istant tuberculosis treated by individual chemotherapy (CT) regimens. Subjects and methods : Totally, 89 children (2-12 years old) with respiratory tuberculosis, they all were exposed to multiple and extensive drug resistant tuberculosis. Patients were divided into three groups: …
Hélène E. Aschmann, Allan Musinguzi, Jillian L. Kadota, Catherine Namale, Juliet Kakeeto, et al.
…le 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens. Methods: We conducted a discrete choice experiment among adult PLHIV engaged in care at an urban HIV clini…
Courtney M. Yuen, Ana Karina Millones, Jerome T. Galea, Daniela Puma, Judith Jiménez, et al.
…pants were asked to vote for preferred preventive treatment regimens and discuss the reasons behind their choices. Coding followed a deductive approach based on prior research, with data-driven codes added. Results In total, 7 (44%) participants voted for 3 months isoniazid and r…
Andrew Nunn
Tuberculosis drug regimens and their efficacies Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL conducts two stages of drug treatment for those with tuberculosis called 'STREAM'. In this clinical trial, stage 1 demonstrated that …
Malik Zohaib Ali, Taru S. Dutt, Amanda Walz, Camron Pearce, Richard Lee, et al.
…fficacy as BPaS regimen. Therefore, we tested BPaL and BPaS regimens in Balb/c (TB resistant) and C3HeB/FeJ (TB susceptible) mice infected with low-dose Mtb, and evaluated bacterial burden using colony-forming units (CFUs). Compared to untreated mice, CFUs in lungs of BPaL and BP…
Timothy M Walker, James A Watson, David A J Moore, Mike Frick, Euzebiusz Jamrozik
… designs have so far led to the implementation of effective regimens of 1-4 months' duration. Such regimens are a substantial improvement on the previous 6-9 months' duration standard of care but still far too long given potential toxicity and the very low baseline risk of diseas…
BLANC François-Xavier, MD, PhD, LAUREILLARD Didier, MD
DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 ce…
Richard E. Chaisson, MD
…drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will eff…
Tanneau L, Karlsson MO, Rosenkranz SL, Cramer YS, Shenje J, et al.
…Furthermore, we predicted the safety profiles of once daily regimens. Data were obtained from a trial where participants were randomized 1:1:1 to receive delamanid, bedaquiline, or delamanid + bedaquiline. The effect on QTcF of delamanid and/or its metabolite (DM-6705) and the ph…
Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, et al.
…pants were asked to vote for preferred preventive treatment regimens and discuss the reasons behind their choices. Coding followed a deductive approach based on prior research, with data-driven codes added. Results In total, 7 (44%) participants voted for 3 months isoniazid and r…
Bai-Yu Lee, Daniel L Clemens, Saša Masleša-Galic, Susana Nava, Chiao-Yueh Lo, et al.
We previously identified a potent 4-drug oral regimen comprising clofazimine, bedaquiline, pyrazinamide, and delamanid (parabolic response surface [PRS] regimen V) that dramatically shortens by approximately 85% the treatment duration needed to attain relapse-free cure of tubercu…
Ira Shah, Dhruv N Gandhi, Ramsha Ansari, Himanshu Warse, Sachi Kalawadia, et al.
…BDQ)-based (without delamanid) antitubercular therapy (ATT) regimens in children aged 5-18 years. **METHODS:** A retrospective study was conducted between June 2021 and February 2024. We included 105 children diagnosed with drug-resistant tuberculosis (DR-TB) and treated with lo…
Tom Yates, Daniel Grint
Treatment regimens for tuberculosis remain protracted and burdensome, both for patients to adhere to and for health-care providers to administer. Particularly, many current regimens for drug-resistant tuberculosis are poorly tolerated by patients and carry an unacceptable side-ef…
Anton C, Lemos CX, Machado FD, Bernardi RM, Freitas AA, et al.
…evaluate the association of use of alternative TB treatment regimens (without rifampicin and isoniazid) and mortality among patients requiring intensive care. Methods Retrospective cohort study, from January 2010 to December 2018. Patients aged > 18 years with a TB diagnosis, adm…
Aschmann HE, Musinguzi A, Musinguzi A, Kadota JL, Namale C, et al.
…le 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens. Methods From July to November 2022, we conducted a discrete choice experiment among adult PLHIV engaged in…
Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, et al.
There is urgent need for new drug regimens that more rapidly cure tuberculosis (TB). Existing TB drugs and regimens vary in treatment-shortening activity, but the molecular basis of these differences is unclear, and no existing assay directly quantifies the ability of a drug or r…
Gugnani JS, Abhishek F, Agarwal Y, Damera AR, Kaur H, et al.
… systematic review article focuses on using rifabutin-based regimens as a treatment option after initial treatments have failed. The authors screened literature published in the last five years, between 2017 and 2022, across various search engines and closely examined relevant st…
Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM
…randomization trial designs to select promising combination regimens in a platform adaptive trial. Methods Clinical trial simulation tools were built using predictive and validated parametric survival models of time to culture conversion (intermediate endpoint) and time to TB-rel…